AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21502454
Drug: Wound-probing protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wound-probing protocol (WPP) with daily probing between staples
Trial: 19254788
Drug: Bazedoxifene (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene (20 and 40 mg daily combined)
Trial: 9270085
Drug: Enalapril combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril combined with hydrochlorothiazide (20/6 mg)
Trial: 8116814
Drug: Ivermectin plus
RxNorm normalized name: clorsulon / ivermectin Injectable Solution [Ivermax Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin plus DEC (400 micrograms/kg plus 1 mg/kg)
Trial: 8116814
Drug: Ivermectin plus
RxNorm normalized name: clorsulon / ivermectin Injectable Solution [Ivermax Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin plus DEC (400 micrograms/kg plus 3 mg/kg)
Trial: 8116814
Drug: Ivermectin plus
RxNorm normalized name: clorsulon / ivermectin Injectable Solution [Ivermax Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin plus DEC (400 micrograms/kg plus 6 mg/kg)
Trial: 8116814
Drug: DEC (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC (6 mg/kg) alone
Trial: 2904883
Drug: verapamil (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil (240 mg)
Trial: 2904883
Drug: atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol (100 mg x day‐1)
Trial: 30113928
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (SSRI + CBT)
Trial: 21969284
Drug: Dextrose injection
RxNorm normalized name: Dextrose Injection
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose injection (12.5% dextrose)
Trial: 21969284
Drug: Lidocaine injection
RxNorm normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine injection (1% lidocaine solution)
Trial: 18360019
Drug: Triple blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple blockade with 25 mg of spironolactone added to ACE-I (5 mg enalapril) and ARB (50 mg losartan)
Trial: 18360019
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with 1 mg of trichlormethiazide or 20 mg of furosemide added to ACE-I and ARB
Trial: 18360019
Drug: Triple blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple blockade with 25 mg of spironolactone added to ACE-I and ARB
Trial: 12516410
Drug: Conventional-medicine (placebo:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-medicine (placebo: glucose, vitamin C, KCl)
Trial: 9302399
Drug: Glycyrrhetinic acid
RxNorm normalized name: Glycyrrhetinic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyrrhetinic acid (170 mg t.d.s.)
Trial: 9302399
Drug: Carbenoxolone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone (100 mg t.d.s.)
Trial: 9302399
Drug: Both inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both inhibitors in combination
Trial: 8475946
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg per day
Trial: 2427835
Drug: Celiprolol (200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (200, 400, or 600 mg once daily)
Trial: 2427835
Drug: Chlorthalidone (12.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (12.5, 25, or 37.5 mg once daily)
Trial: 29793629
Drug: Canakinumab (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab (50, 150, or 300 mg) given subcutaneously once every 3 months
Trial: 23548062
Drug: 4% dimeticone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% dimeticone liquid gel applied once for 15 minutes
Trial: 16541858
Drug: Acupuncture once
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acupuncture once daily
Trial: 16541858
Drug: Acupuncture twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture twice each week
Trial: 14719212
Drug: Etidronate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate (200 mg per day for 2 weeks) with 3.0 g calcium lactate and 0.75 microg alphacalcidol
Trial: 14719212
Drug: Control (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (3.0 g calcium lactate and 0.75 microg alphacalcidol)
Trial: 11272799
Drug: Electroacupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture and conventional therapy for four weeks
Trial: 6880227
Drug: Cimetidine 1
RxNorm normalized name: cimetidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1 g/day for 8 weeks
Trial: 6880227
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg at night after full-dose course
Trial: 30107787
Drug: Regular weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular weekly exercise program (Control group)
Trial: 7783110
Drug: Felodipine ER
RxNorm normalized name: Felodipine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine ER (mean daily dose 11.2 mg)
Trial: 7783110
Drug: Amlodipine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (mean daily dose 7.4 mg)
Trial: 6253100
Drug: Cyclizine and
RxNorm normalized name: Cyclizine and morphine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclizine and Metoclopramide (combination)
Trial: 30898825
Drug: Supported self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supported self-management Smartphone app (My Journey 3) plus Treatment As Usual (TAU)
Trial: 30898825
Drug: Treatment As
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment As Usual (TAU) only
Trial: 25816197
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of olmesartan and amlodipine
Trial: 19484832
Drug: Early iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early iron supplementation (3-4 mg/kg/day orally from 2 weeks)
Trial: 7829787
Drug: Nitroglycerin patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin patches (50 mg)
Trial: 7829787
Drug: Nitroglycerin patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin patches (50 mg) during patch-off period
Trial: 7829787
Drug: Placebo patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patches during patch-off period
Trial: 7829787
Drug: Nitroglycerin patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin patches (50 mg) during patch-on period
Trial: 7829787
Drug: Placebo patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patches during patch-on period
Trial: 18234905
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course antibiotic treatment (<= 5 days)
Trial: 18234905
Drug: Conventional longer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional longer antibiotic treatment (> 5 days)
Trial: 14669316
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine (NAC) 200 mg orally three times daily (600 mg/day)
Trial: 8996853
Drug: New sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New sustained-release theophylline formulation (T1)
Trial: 8996853
Drug: New sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New sustained-release theophylline formulation (T2)
Trial: 1613812
Drug: Nimodipine, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine, 2 mg/h iv for 2 days
Trial: 6238545
Drug: Ipratropium (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium (active drug)
Trial: 26903147
Drug: Twice-weekly intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly intensive aerobic exercise for 12 weeks (60 minutes per session, intensity up to exertion level 14 or 15 on the Borg scale)
Trial: 26903147
Drug: Twice-weekly intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly intensive aerobic exercise for 12 weeks
Trial: 19761492
Drug: Prucalopride, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride, a selective 5-HT(4) agonist given orally once daily for 12 weeks
Trial: 18562740
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of bisacodyl
Trial: 18562740
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of bisacodyl
Trial: 18562740
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of bisacodyl and 8.2 g of magnesium citrate
Trial: 18562740
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of bisacodyl and 16.4 g of magnesium citrate
Trial: 18562740
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (30 mg of bisacodyl)
Trial: 16447661
Drug: Fluoxetine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (oral medication)
Trial: 11810086
Drug: Concurrent oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent oxytocin with sustained-release dinoprostone insert (immediate group)
Trial: 1791685
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (EGb 761) 160 mg/day
Trial: 1791685
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (EGb 761) 80 mg/day
Trial: 29295825
Drug: Intravenous belimumab
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous belimumab 10 mg/kg plus standard of care (SoC) every 4 weeks until Week 48
Trial: 25409961
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (Gpre, Gintra, Gpos)
Trial: 22385023
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese acupuncture (TCA) weekly sessions for 5 weeks
Trial: 22385023
Drug: Attention only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attention only weekly sessions for 5 weeks
Trial: 20082362
Drug: Minimum effective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimum effective dose estimation
Trial: 17646754
Drug: Antifibrotic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifibrotic agents (general)
Trial: 12065553
Drug: No maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No maintenance therapy (MT)
Trial: 9452837
Drug: Sequential-gradient calf
RxNorm normalized name: thymus gland-calf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential-gradient calf compression
Trial: 2090773
Drug: Lorazepam 2.5
RxNorm normalized name: lorazepam 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 2.5 mg orally prior to chemotherapy and repeated after 12 hours (Arm A)
Trial: 626712
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 8‐methoxypsoralen followed by high‐intensity longwave ultraviolet treatment
Trial: 626712
Drug: Conventional ultraviolet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ultraviolet light therapy
Trial: 30793642
Drug: Anifrolumab 100
RxNorm normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anifrolumab 100 mg IV
Trial: 30793642
Drug: Anifrolumab 300
RxNorm normalized name: ANIFROLUMAB 300 mg in 2.0 mL INTRAVENOUS INJECTION, SOLUTION [SAPHNELO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anifrolumab 300 mg IV
Trial: 30793642
Drug: Anifrolumab 1000
RxNorm normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anifrolumab 1000 mg IV
Trial: 27611637
Drug: Inhaled sevoflurane
RxNorm normalized name: sevoflurane Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled sevoflurane for 48 hours
Trial: 23578606
Drug: HPβCD-diclofenac 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPβCD-diclofenac 37.5 mg
Trial: 23578606
Drug: HPβCD-diclofenac 75
RxNorm normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPβCD-diclofenac 75 mg
Trial: 20681817
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal therapy (including oral hygiene instructions, scaling and root planing, and systemic antibiotic therapy)
Trial: 19258557
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin K, 1.25 mg
Trial: 11281051
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose thiopentone (4 mg.kg‐1) administered just before laryngoscopy and intubation
Trial: 11281051
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (thiopentone 4 mg.kg‐1 for induction, suxamethonium 1.5 mg.kg‐1 for muscle relaxation)
Trial: 11050785
Drug: Relevant repeat
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relevant repeat prescription since diagnosis
Trial: 11050785
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with aspirin or a lipid-lowering agent
Trial: 1536941
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (IC) with VAD regimen (vincristine, doxorubicin, dexamethasone) or VMCP regimen (vincristine, melphalan, cyclophosphamide, prednisone)
Trial: 1536941
Drug: High-dose melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melphalan with total body irradiation supported by unpurged autologous bone marrow transplantation (ABMT)
Trial: 1536941
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) alpha maintenance treatment
Trial: 6655706
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for couples not divorced or given additional therapy
Trial: 6655706
Drug: Couples given
RxNorm normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couples given additional therapy
Trial: 15765257
Drug: Pergolide (mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pergolide (mixed D1/D2 agonist)
Trial: 15765257
Drug: Bromocriptine (D2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (D2 selective agonist)
Trial: 8929934
Drug: High attendance
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High attendance or Enhanced Care group (average of 4.1 treatment days per week)
Trial: 8929934
Drug: Low attendance
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low attendance or Usual Care and Medium attendance groups (less than one treatment day per week)
Trial: 30575978
Drug: E6011 (0.0006-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6011 (0.0006-10 mg/kg)
Trial: 16941239
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment control (NT)
Trial: 16281522
Drug: Methanthelinium bromide
RxNorm normalized name: Methanthelinium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methanthelinium bromide 50 mg orally twice daily for 4 weeks
Trial: 9289631
Drug: 20% sucralfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% sucralfate suspension
Trial: 9289631
Drug: 1 gram
RxNorm normalized name: guar gum 1 gram ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram sucralfate chewable tablets
Trial: 8214949
Drug: Flurbiprofen (prostaglandin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (prostaglandin synthetase inhibitor)
Trial: 3612641
Drug: Multivitamin/multimineral with
RxNorm normalized name: Multivitamin/Multimineral with Folic acid Oral tablet, biphasic release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin/multimineral with 65 mg of iron
Trial: 26263033
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen (2.4 ± 0.7 L/min)
Trial: 23857313
Drug: Dichoptic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichoptic treatment combined with visual cortex direct current stimulation
Trial: 23857313
Drug: Dichoptic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichoptic treatment alone
Trial: 8853223
Drug: ondansetron 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 0.25 mg bd
Trial: 25342704
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein (HP) beverage (1.5 g/100 ml)
Trial: 25342704
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein (LP) beverage (0.75 g/100 ml)
Trial: 25342704
Drug: Control (CON)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (CON) beverage (0 g/100 ml)
Trial: 23576048
Drug: Casein (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein (30 g, 15N-labeled)
Trial: 23576048
Drug: Whey proteins
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey proteins (30 g)
Trial: 29331328
Drug: Conventional oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oxygen therapy (control)
Trial: 18051216
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with a high-dose, standardized, 3-grass pollen extract
Trial: 16087920
Drug: Levodopa (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (single oral dose)
Trial: 9305335
Drug: Gabapentin 2400
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 2400 mg/d
Trial: 30509271
Drug: Empagliflozin/Metformin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin/Metformin (25 mg and 2000 mg daily, respectively)
Trial: 23086332
Drug: G-Bond (GB,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-Bond (GB, GC)
Trial: 21946199
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy + anti-Helicobacter pylori therapy
Trial: 10868867
Drug: Active PENS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active PENS treatment
Trial: 8173690
Drug: Felodipine-metoprolol combination
RxNorm normalized name: felodipine / metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine-metoprolol combination tablet (extended-release), administered once daily, dosage individually titrated until blood pressure control achieved.
Trial: 8173690
Drug: Felodipine-metoprolol combination
RxNorm normalized name: felodipine / metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine-metoprolol combination tablet (extended-release) for 24 months (Swedish/UK study).
Trial: 8173690
Drug: Felodipine-metoprolol combination
RxNorm normalized name: felodipine / metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine-metoprolol combination tablet (extended-release) with hydrochlorothiazide added if necessary (12.5 or 25 mg daily).
Trial: 8173690
Drug: Felodipine-metoprolol combination
RxNorm normalized name: felodipine / metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine-metoprolol combination tablet (extended-release).
Trial: 26908839
Drug: Gonadotropin suppression
RxNorm normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin suppression (testosterone enanthate + GnRH antagonist acyline)
Trial: 26908839
Drug: Gonadotropin suppression
RxNorm normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin suppression (testosterone enanthate + levonorgestrel + GnRH antagonist acyline)